Blood test may reveal if breast cancer treatment is working

NCT ID NCT07662252

Not yet recruiting Knowledge-focused Sponsor: Federico II University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether tracking tumor DNA in the blood (ctDNA) can help doctors see how well breast cancer treatment is working before surgery. It will include 186 people with stage II-III HER2-positive or triple-negative breast cancer. Researchers will take blood samples at key points during standard treatment to see how quickly the tumor DNA disappears.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a blood test that helps doctors quickly tell if breast cancer treatment is working, allowing them to adjust therapy sooner.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly improve outcomes. The findings may not apply to all patients or lead to a usable test.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER HER2 + BREAST CANCER TRIPLE-NEGATIVE BREAST CANCER (TNBC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.